Drug Trial Radar · NCT07382531
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 7, 2023
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Binhui Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
BS008-001 is a multicenter, open-label phase Ib /II trial in heavily pre-treated patients with advanced solid tumors. Patients received biweekly sequential intratumoral injections of OH2 (fixed dose: 10⁷ CCID₅₀/mL) followed by BS006 (dose escalation: 10⁶-10⁷ CCID₅₀/mL), with identical volumes being injected at the same lesion. The primary endpoint is safety and tolerability; secondary endpoints included efficacy outcomes assessed by RECIST 1.1/iRECIST.
Conditions
- Solid Tumor
Interventions
OH2+BS006Biological
Patients received biweekly sequential intratumoral injections of OH2 (fixed dose: 10⁷ CCID₅₀/mL) followed by BS006 (dose escalation: 10⁶-10⁷ CCID₅₀/mL), with identical volumes being injected at the same lesion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AE (Adverse Event) and SAE (Serious Adverse Event)Time frame: Through study completion, six months after the last administration of the study drug to the last enrolled subject.
- DLTs (Dose Limiting Toxicity)Time frame: 4 weeks from the first administration
- MTDTime frame: Through study completion, six months after the last administration of the study drug to the last enrolled subject.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.